EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Exploring current and emerging therapies for porphyrias

Daniel Jericó iD, Karol M Córdoba iD, Francesco Urigo iD, Rafael Enríquez de Salamanca iD, Karl E Anderson iD, Jean-Charles Deybach iD, Matías A Ávila iD, Antonio Fontanellas iD

Liver International · 2024

DOI: 10.1111/liv.15979 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, 2024. Verfasst von Daniel Jericó und 7 weiteren Autor:innen. Beteiligte Einrichtung: Solid Tumors Program, Hepatology: Porphyrias & Carcinogenesis Laboratory, CIMA-University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Drug Delivery Systems. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Spanish Institute of Health Carlos III, Fundación Mutua Madrileña, Fundación Eugenio Rodríguez Pascual.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Porphyrias are rare, mostly inherited disorders resulting from altered activity of specific enzymes in the haem synthesis pathway that lead to accumulation of pathway intermediates. Photocutaneous symptoms occur when excess amounts of photoreactive porphyrins circulate in the blood to the skin, whereas increases in potentially neurotoxic porphyrin precursors are associated with neurovisceral symptoms. Current therapies are suboptimal and their mechanisms are not well established. As described here, emerging therapies address underlying disease mechanisms by introducing a gene, RNA or other specific molecule with the potential to cure or slow progression of the disease. Recent progress in nanotechnology and nanoscience, particularly regarding particle design and formulation, is expanding disease targets. More secure and efficient drug delivery systems have extended our toolbox for transferring specific molecules, especially into hepatocytes, and led to proof‐of‐concept studies in animal models. Repurposing existing drugs as molecular chaperones or haem synthesis inhibitors is also promising. This review summarizes key examples of these emerging therapeutic approaches and their application for hepatic and erythropoietic porphyrias.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Delivery SystemsHumansAnimalsPorphyriasHemePorphyrinsGenetic TherapyPorphyria, ErythropoieticPorphyrias, HepaticDrug Repositioning

Stichwörter der Autor:innen

RNA interference technologyantisense oligonucleotide therapychaperonedirect‐acting antiviral agentsdrug repositioninghaem synthesisintracellular transport inhibitormRNA formulated in lipid nanoparticlesmelanogenesis stimulatorporphyrias

Substanzen

HemePorphyrins

Autor:innen und Institutionen

  • Solid Tumors Program, Hepatology: Porphyrias & Carcinogenesis Laboratory, CIMA-University of Navarra, Pamplona, Spain.
  • Department of Internal Medicine, Reference Center for Inherited Metabolic Disease-MetabERN, University Hospital 12 de Octubre, UCM, Madrid, Spain.
  • Porphyria Laboratory and Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
  • French Porphyria Reference Center (CRMR Porphyries France), Université Paris, Paris, France.
  • Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Daniel Jericó, Karol M Córdoba, Francesco Urigo, Rafael Enríquez de Salamanca, Karl E Anderson, Jean-Charles Deybach, Matías A Ávila, Antonio Fontanellas

Förderung

  • Spanish Institute of Health Carlos III
  • Fundación Mutua Madrileña
  • Fundación Eugenio Rodríguez Pascual

Zitieren

APA

Jericó, D., Córdoba, K. M., Urigo, F., Enríquez de Salamanca, R., Anderson, K. E., Deybach, J. C., Ávila, M. A., & Fontanellas, A. (2024). Exploring current and emerging therapies for porphyrias. Liver International. https://doi.org/10.1111/liv.15979

Vancouver

Jericó D, Córdoba KM, Urigo F, Enríquez de Salamanca R, Anderson KE, Deybach JC, et al. Exploring current and emerging therapies for porphyrias. Liver International. 2024. doi:10.1111/liv.15979

BibTeX
@article{Jeric2024,
  author = {Jericó, Daniel and Córdoba, Karol M and Urigo, Francesco and Enríquez de Salamanca, Rafael and Anderson, Karl E and Deybach, Jean-Charles and Ávila, Matías A and Fontanellas, Antonio},
  title = {Exploring current and emerging therapies for porphyrias},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15979}
}
Kostenlos starten →